LYMPHOMAS

Treatment with IGM-2323, a bispecific IgM antibody, resulted in tumor shrinkage in 9 of 14 patients with CD20-positive relapsed/refractory non-Hodgkin lymphoma in a phase 1 study.

In patients with relapsed or refractory lymphoma, treatment with the investigational CD47-blocker TTI-622 appeared well tolerated and demonstrated preliminary activity, according to results from a phase 1a clinical trial presented in a poster during the 2020 American Society of Hematology Virtual Annual Meeting.

Treatment with axicabtagene ciloleucel resulted in high rates of durable responses in patients with indolent non-Hodgkin lymphoma.

Placebo following a fixed-treatment duration of ibrutinib combined with venetoclax achieved similar 1-year disease-free survival results compared with patients who remained on ibrutinib following confirmed undetectable minimal residual disease in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Patients with refractory large B-cell lymphoma experienced long-term disease control with rapid responses and robust CAR T-cell expansion with the CAR T-cell therapy axicabtagene ciloleucel.

In a phase 1 study of patients with relapsed/refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, the anti-inducible T-cell co-stimulator monoclonal antibody MEDI-570 demonstrated activity, durable responses, safety, and tolerability.

The incorporation of genomics into the classification and treatment decision-making process for lymphomas is possible; however, many obstacles have prevented the incorporation of sequencing into standard practice, according to Sandeep Dave, MD.

The FDA will not complete its review of the Biologics License Application for lisocabtagene maraleucel for the treatment of patients with relapsed/refractory large B-cell lymphoma after 2 prior lines of therapy by the Prescription Drug User Fee Act action date of November 16, 2020.

A general framework can be utilized to guide treatment decision in patients with follicular lymphoma, according to John P. Leonard, MD. During a presentation for the 38th Annual Chemotherapy Foundation Symposium, Leonard also explained that bulk of disease, comorbidities, and toxicity, among others are all factors that impact treatment decisions.

Andre Goy, MD, MS, discusses the benefits of working with a pathologist to develop a better understanding of molecular oncology and optimal treatment decisions for patients with lymphomas.

The CLOVER-1 study is testing CLR 131 in patients with relapsed or refractory non-Hodgkin lymphoma, including lymphoplasmacytic lymphoma and Waldenström macroglobulinemia.

The FDA granted approval to the immune checkpoint inhibitor pembrolizumab as treatment of patients with relapsed or refractory classic Hodgkin lymphoma.

Marginal zone lymphomas are a heterogenous group of B-cell non-Hodgkin lymphomas based on their etiology and clinical presentation, and as such, treatment for these diseases vary by subtype, according to Stephen Douglas Smith, MD.

When choosing therapy for patients with early stage Hodgkin lymphoma, considering risk scoring systems and Deauville criteria for PET-adapted therapy are key conditions for optimizing survival rates, according to Ranjana H. Advani, MD.

The most recent updated World Health Organization classification of lymphoid neoplasms included a new category of mature B-cell neoplasms, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations.

During a Targeted Oncology Case Based Peer Perspective event, Barbara Pro, MD, discussed the case of a 60-year-old male patient with peripheral T-cell lymphoma.

Lori A. Leslie, MD, discusses the approval of tazemetostat in the follicular lymphoma setting and the data that that led to its FDA approval.

“We should look to reduce or limit radiation therapy or eliminate it if it’s not necessary. The major problem is the late toxicity associated with it."

Nilanjan Ghosh, MD, PhD, discussed the case of a 22-year-old patients with advanced Hodgkin lymphoma.

The FDA accepted a supplemental New Drug Application for crizotinib and granted it a Priority Review as treatment of pediatric patients with relapsed or refractory systemic anaplastic large cell lymphoma that is positive for an ALK alteration.

In an interview with Targeted Oncology, Thomas M. Habermann, MD, reflects on the advancements he has observed in the treatment paradigm for lymphomas.

Patients with classic Hodgkin lymphoma and human immunodeficiency virus were found to have similar clinical outcomes compared with patients with cHL and no HIV, according to an analysis presented during the eighth annual virtual meeting of the Society of Hematologic Oncology.

In an interview with Targeted Oncology, Alan P. Z. Skarbnik, MD, discussed the current therapeutic strategies for treating patients with FL.

John M. Burke, MD, discusses treatment with rituximab versus obinutuzumab in patients with advanced stage follicular lymphoma with high tumor burden.

The FDA has accepted a supplemental Biologics License Application for axicabtagene ciloleucel for the treatment of patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma after 2 or more prior lines of systemic therapy.